Informing patients about tardive dyskinesia: A survey of clinicians' attitudes in three countries

International Journal of Law and Psychiatry

Volumn 27, Issue 1, 2004, Pages 101-108

  Laugharne, Jon ^a   Davies, Alison ^b   Arcelus, Jon ^c   Bouman, Walter Pierre ^d  

^a Osborne Clinic   (Australia)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

^c Oaklands Centre   (United Kingdom)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ATTITUDE; HUMAN; INFORMED CONSENT; PATIENT EDUCATION; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; TARDIVE DYSKINESIA; VALIDATION PROCESS;

EID: 1542329055     PISSN: 01602527     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijlp.2003.12.004     Document Type: Article

References (19)

1. American Psychiatric Association Tardive dyskinesia: A task force report of the American Psychiatric Association. 1992;APA, Washington, DC.
2. Benson P.R. Informed consent. Drug information disclosed to patients prescribed anti-psychotic medication. The Journal of Nervous and Mental Disease. 172:1984;642-653.
3. Brabbins C., Butler J., Bentall R. Consent to neuroleptic medication for schizophrenia: Clinical, ethical and legal issues. British Journal of Psychiatry. 168:1996;540-544.
4. Chaplin R., Kent A. Informing patients about tardive dyskinesia. British Journal of Psychiatry. 172:1998;78-81.
5. Chaplin R., Potter M. Tardive dyskinesia: Screening and risk disclosure. Psychiatric Bulletin. 20:1996;714-716.
6. Department of Health and the Welsh Office Mental health act 1983 code of practice. 1993;HMSO, London.
7. Gillon R. Philosophical medical ethics. 1986;Wiley, Chichester, UK.
8. Ingelfinger F.J. Informed (but uneducated) consent. New England Journal of Medicine. 287:1972;465-466.
9. Johnstone E.C. Schizophrenia: Problems in clinical practice. Lancet. 341:1993;536-538.
10. Jones G.H. Informed consent in chronic schizophrenia? British Journal of Psychiatry. 167:1995;565-568.
11. Kleinman I., Schacter D., Koritar E. Informed consent and tardive dyskinesia. American Journal of Psychiatry. 416:1989;902-904.
12. Laugharne J., Brown S. Informed consent and antipsychotic use in patients with schizophrenia - Issues and recommendations. CNS Drugs. 9:1998;1-5.
13. Laugharne J., Davies A., Arcelus J. Consent to treatment. [Letter] British Journal of Psychiatry. 169:1996;382.
14. MacPherson R., Jerrom B., Hughes A. A controlled study of education about drug treatment in schizophrenia. British Journal of Psychiatry. 168:1996;709-717.
15. Munetz M.R., Roth L.H. Informing patients about tardive dyskinesia. Archives of General Psychiatry. 42:1985;866-871.
16. Rogers A., Pilgrim D., Lacey R. Experiencing psychiatry: Users' views of services. 1993;Macmillan/MIND, London.
17. Simon R.I. Clinical psychiatry and the law. 1987;American Psychiatric Press, Washington, DC.
18. Simpson G.M. The treatment of tardive dyskinesia and tardive dystonia. Journal of Clinical Psychiatry. 61(Suppl. 4):2000;39-44.
19. Tyrer P., Smith J., Adshed G. Ethical dilemmas in drug treatments. Psychiatric Bulletin. 18:1994;203-204.